New Hampshire committee considers making ivermectin available over the counter

In a recent meeting of the New Hampshire House Health, Human Services and Elderly Affairs Committee, a passionate discussion unfolded around the potential for making ivermectin available over the counter. Advocates for the change highlighted the drug's long-standing safety record and its historical significance in treating various parasitic diseases, including river blindness and lymphatic filariasis. They pointed out that ivermectin has been administered over four billion times globally and is recognized by the World Health Organization as an essential medicine.

The conversation was sparked by a proposal to amend existing legislation, which had previously been vetoed by the governor in 2022. Proponents argued that allowing over-the-counter access to ivermectin would empower individuals to manage their health more effectively and alleviate pressure on healthcare providers. They emphasized that the drug carries a lower risk than many common over-the-counter medications, such as pain relievers.

However, the discussion was not without contention. Some committee members raised concerns about the implications of allowing pharmacists to dispense ivermectin without a prescription. They pointed out that while the drug is generally safe, it is not without risks, particularly for certain populations, such as pregnant women or those with specific health conditions. The chief medical officer for the New Hampshire Department of Health and Human Services noted that the FDA classifies ivermectin as a prescription medication due to these safety concerns.

Pharmacists also voiced their apprehensions, emphasizing the need for proper training and protocols to ensure safe dispensing practices. They argued that the proposed amendment could add significant burdens to an already strained healthcare system, potentially leading to conflicts between pharmacists and patients.

As the meeting progressed, it became clear that the debate over ivermectin is emblematic of broader discussions about public health, personal freedom, and the role of government in healthcare. While some committee members expressed optimism about the potential for change, others cautioned against rushing into legislation that could have unintended consequences.

The committee ultimately faced a pivotal decision: whether to align state policy with the growing trend in other states and countries that have embraced over-the-counter access to ivermectin or to uphold the existing prescription requirements that prioritize patient safety. As the meeting concluded, the future of ivermectin access in New Hampshire remained uncertain, leaving many to ponder the balance between individual rights and public health responsibilities.